European Medicines Agency validates marketing application for Filgotinib for the treatment of rheumatoid arthritis

Gilead Sciences and Galapagos announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). “We are excited about the validation of this application which is an important

Read More


Tissue model reveals role of blood-brain barrier in Alzheimer’s

Study finds that Alzheimer’s damage allows toxins to enter the brain, further harming neurons. Beta-amyloid plaques, the protein aggregates that form in the brains of Alzheimer’s patients, disrupt many brain functions and can kill neurons. They can also damage the blood-brain barrier — the normally tight border that prevents harmful molecules in the bloodstream from

Read More


Characterizing tau aggregates in neurodegenerative diseases

New research reveals a structural model for amyloid fibrils that could aid in future medicinal interventions for Alzheimer’s, CTE, and more. The microtubule-binding protein tau in neurons of the central nervous system can misfold into filamentous aggregates under certain conditions. These filaments are found in many neurodegenerative diseases such as Alzheimer’s disease, chronic traumatic encephalopathy

Read More


Leading oncologists and nutritionists pinpoint key areas to catalyze nutrition-based cancer prevention research and interventions

An international collaborative led by Ludwig Cancer Research and Cancer Research UK has identified key areas that are central to uncovering the complex relationship between nutrition and cancer. Advancing research on these core areas using a holistic, cross-disciplinary approach could catalyze progress urgently needed to prevent cancer and improve public health globally. Their main observations

Read More


GSK gets EC approval for new administration options of asthma treatment Nucala

GlaxoSmithKline (GSK) has secured marketing authorisation from the European Commission (EC) for two new administration options of Nucala (mepolizumab) to treat patients with severe eosinophilic asthma. Nucala, a pre-filled pen and a pre-filled safety syringe, is claimed to be the only monthly anti-IL5 biologic approved in Europe to treat patients with severe eosinophilic asthma at

Read More


Some health websites are notoriously misleading: their reliability rated

Source STAT For millions of Americans, including health professionals, the resurgence of measles is a confounding and frightening development. How can a disease declared eliminated nearly two decades ago come back when it can be prevented with a vaccine proven to be safe and effective? But that’s not the reality for those getting their health information from

Read More